Vir Biotech reports HBsAg loss in MARCH study but halts Phase 3 for chronic HBV without partner

Vir Biotechnology, Inc.

HBsAg loss 24 weeks post-treatment: 17% (3/18) and 21% (3/14) in low baseline HBsAg patients with tobevibart+elebsiran without/with PEG-IFNα.
No global development partner secured for chronic HBV; Phase 3 will not proceed.
Company to streamline final stages of MARCH Phase 2, focusing on hepatitis delta ECLIPSE Phase 3 and T-cell engager oncology programs.
Cash runway guidance into mid-2027 reaffirmed based on current operating plan.
Safety profile consistent; no new concerns; generally mild/moderate adverse events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.